| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/10/2005 | US20050032891 Method for treating alcoholic hepatitis |
| 02/10/2005 | US20050032890 Aniline-derived ligands for the thyroid receptor |
| 02/10/2005 | US20050032887 Novel lactone compound |
| 02/10/2005 | US20050032886 Use of parthenolide derivatives as antileukemic and cytotoxic agents |
| 02/10/2005 | US20050032885 Use as pesticides, microbicides and herbicides; compatible with crop plants |
| 02/10/2005 | US20050032882 Botanical extract compositions and methods of use |
| 02/10/2005 | US20050032880 Dissolving atorvastatin in alcoholic solvent comprising methanol, ethanol, 1-propanol, or isopropanol; high speed evaporation by spray drying |
| 02/10/2005 | US20050032879 Formulations and use of a beta-blocker and an ACE-inhibitor for the treatment of cardiovascular diseases |
| 02/10/2005 | US20050032878 Peroxisome proliferator activated compound of fenofibrate, ciprofibrate, clofibrate, gemifibrozil and/or bezafibrate; and pravastatin, simvastatin, lovastatin, fluvastatin, atorvastatin, cerivastatin, pravastatin and/or mixtures; and polyglycolized glyceride; dissolving, bioavailability |
| 02/10/2005 | US20050032877 Method and composition for treating burned skin |
| 02/10/2005 | US20050032876 Pharmaceutical compositions comprising sumatriptan and metoclopramide, and methods of use thereof |
| 02/10/2005 | US20050032874 Indole derivatives |
| 02/10/2005 | US20050032871 Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors |
| 02/10/2005 | US20050032870 Administering as anticarcinogenic agent |
| 02/10/2005 | US20050032869 Antitumor, anticarcinogenic, antiproliferative, and antimetastasis agents; tyrosine kinase inhibitors; autoimmune, nervous system, neurodegenerative, and skin disorders; neurofibromatosis, atherosclerosis, graft versus host disease, glomerulonephritiis, hyperplasia; angiogenesis inhibitors |
| 02/10/2005 | US20050032868 Selected substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists |
| 02/10/2005 | US20050032867 Pharmaceutical composition comprising a 5ht1 receptor agonist |
| 02/10/2005 | US20050032866 Administering N-[(1-butyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide or salt as antiarrhythmia agent |
| 02/10/2005 | US20050032865 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging |
| 02/10/2005 | US20050032863 Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor |
| 02/10/2005 | US20050032862 Preparing a novel crystal form by sonication and temperature oscillation of a suspension; filtered and dried faster; treating cardiovascular disorders |
| 02/10/2005 | US20050032861 Antibiotic (vancomycin) resistant Grampositive and Gramnegative bacteria; cycloadditon, reduction, coupling, salt formation, deprotecting, amination, oxidation |
| 02/10/2005 | US20050032860 CBI analogs of CC-1065 and the duocarmycins |
| 02/10/2005 | US20050032858 Novel heterocyclic compound and anti-inflamatory agent |
| 02/10/2005 | US20050032857 Administering 3-(2-hydroxyethyl)-2-[2-[[3-(2-hydroxyethyl)-5-methoxy-2-benzothiazolylidene]methyl]-1-butenyl]-5-methoxybenzothiazolium derivative or salt to treat nervous system and brain disorders; Alzheimer*s disease |
| 02/10/2005 | US20050032856 Use of pramipexole to treat amyotrophic lateral sclerosis |
| 02/10/2005 | US20050032854 Administering 2-ethoxy-1-[[2'-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid or a salt as a hypotensive or an antidiabetic agent; impaired glucose tolerance |
| 02/10/2005 | US20050032852 1-(N-substituted sulfonamido),4-(substituted isooxazoly-4-yl)benzenes, e.g., N-ethyl-4-(5-methyl-3-phenylisoxazol-4-yl)-N-propionylbenzenesulfonamide; side effect reduction; solubility; stability; bioavailability, i.e., readily penetrate membranes; non-steroidal antiinflammatory agents; analgesics |
| 02/10/2005 | US20050032851 E. g.,N-[[4-[2-(5-Methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]phenyl]sulfonyl]acetamide; side effect reduction; non-steroidal antiinflammatory agents; antiarthritic agents; analgesics; antipyretics; acylation of the corresponding sulfoamide by an anhydride a solvent and base |
| 02/10/2005 | US20050032850 Administering an (alpha , alpha -disubstituted arylalkyl) (heterocyclylalkyl) amine, e.g., N-[2-Hydroxy-3-(4-(2-carboxamido)indoloxy)propyl]-1,1-dimethyl-2-(4-methoxyphenyl)ethylamine, to treat bone disorders such as osteoporosis, Paget's disease, and periodontal disease |
| 02/10/2005 | US20050032849 Substituted small-molecule arylthiourea compounds are potent and/or selective inhibitors of viral replication in vivo, particularly Hepatitis C virus replication; e.g., 1-(3-benzyloxy)phenylthiourea; side effect reduction |
| 02/10/2005 | US20050032846 Pharmaceutical compositions including pyridines, pyrimidines, purinones, pyrrolopyrimidinones and pyrrolopyridinones along with a carrier to treat certain central nervous system (CNS) and other disorders; cardiovascular, skin pshychological, gastrointestinal, urogenital and heurodegenerative disorders |
| 02/10/2005 | US20050032845 1,1-and 1,2-disubstituted cyclopropane compounds |
| 02/10/2005 | US20050032844 Screening for substances that regulate the metabolic conversion of nicotine to cotinine such as enzyme inhibiters of CYP2A6, a member of the cytochrome P450 (CYP) system and the major nicotine metabolizing enzyme in human livers; also assaying for selective inhibitors of the gene expression of CYP2A6 |
| 02/10/2005 | US20050032843 Dopamine D1, D2, D3, and D4 receptor agonist such as pramipexole in combination with a second active substance selected from D1, D2, D3, and D4 receptor agonists, anorectics, lipase inhibitors and sympathomimetics; for treating overweight or obesity or type 2 diabetes |
| 02/10/2005 | US20050032842 Omeprazole Form A characterized in being being more thermodynamically stable at room temperature and less hygroscopic than omeprazole Form B; heat resistance; photostability; crystallization of a dissolved omeprazole of any form; gastrointestinal disorders; antiulcer agents; campylobacter infections |
| 02/10/2005 | US20050032841 Enzyme inhibitors of ceramide glucosyltransferase or agents capable of increasing the rate of neuronal glycolipid degradation in treating of mucopolysaccharidosis diseases; e.g., N-butyldeoxynojirimycin and other imino sugars and genetic approaches; synergistic effect on activity of glucocerebrosidase |
| 02/10/2005 | US20050032840 Administering the analgesic, 2-methyl-1-(1-piperidinyl)-(2-thienyl)cyclohexane (gacyclidine), by itself or in conjuction with another analgesic; prevention and/or treating pain and/or nociception; preventing hyperalgias and/or allodynias induced by an analgesic acting on opiate receptors |
| 02/10/2005 | US20050032839 Useful in therapy and treatment of diseases associated with a disregulated protein kinase activity like cancer; Aurora kinases |
| 02/10/2005 | US20050032838 Nicotinamide derivatives useful as PDE4 inhibitors |
| 02/10/2005 | US20050032837 For therapy of irritable bowel syndrome, drug addiction or dependency, including alcohol addiction, depression, anxiety, schizophrenia, anxiety, schizophrenia and eating disorders |
| 02/10/2005 | US20050032836 antipsychotic agents with a polylactide-co-glycolide extended release formulation; intramuscular or subcutaneous injections |
| 02/10/2005 | US20050032835 Compositions and methods for inhibiting TGF-beta |
| 02/10/2005 | US20050032834 Administering a chloroquine compound as an anticarcinogenic, antiischemic, anticholesterol, or anxiolytic agent |
| 02/10/2005 | US20050032832 Substituted 2-phenyl-4-quinolone-3-carboxylic acid compounds and their use as antitumor agents |
| 02/10/2005 | US20050032831 Histone deacetylase inhibitors and methods of use thereof |
| 02/10/2005 | US20050032830 Ether substituted imidazopyridines |
| 02/10/2005 | US20050032829 Process for imidazo[4,5-c]pyridin-4-amines |
| 02/10/2005 | US20050032828 E. g., 4-[3-Isopropyl-3-(2-mercapto-benzothiazol-6-yl)-ureido]-piperidine-1-carboxylic acid benzyl ester; metabolic diseases; management/treatment glucose/fatty acid pathway; cardiovascular disorders; congestive heart failure; angina pectoris; antidiabetic agent, anticarcinogenic agents; obesity |
| 02/10/2005 | US20050032827 Sigma ligands for neuronal regeneration and functional recovery |
| 02/10/2005 | US20050032826 Medical devices containing rapamycin analogs |
| 02/10/2005 | US20050032825 rapamaycin derivatives used as fungicides, anticarcinogenic agents, immunosuppressants or as coatings on drug eluting stents to prevent restenosis |
| 02/10/2005 | US20050032824 E. g., 1-Cyano-3-(2-mercaptobenzothiazol-6-yl)-2-phenylisourea; metabolic diseases; management of the glucose/fatty acid pathway; antilipemic agents; cardiovascular diseases; antidiabetic agents; anticarcinogenic agents; obesity; more profound effects in metabolism shift than ranolazine or trimetazidine |
| 02/10/2005 | US20050032823 analgesics; antipyretics; antiinflammatory agents; antiarthritic agents |
| 02/10/2005 | US20050032822 E.g., 5-dinitro-2-dimethyldithio-carbamoyl-pyridine; strong bacteriacidal activity, especially against mycobacteria; tuberculosis and leprosy caused by mycobacteria and infectious diseases caused by staphylococci; side effect reductions; effective against drug, multidrug-resistant infections |
| 02/10/2005 | US20050032821 2-etherified 4-fluoroalkyl-6-(p-sulfonylphenyl)pyrimidines,e.g., 2-(4-fluorophenoxy)-4-[4-(methylsulfonyl)phenyl]-6](trifluoromethyl)pyrimidine; treatment of the pain, fever and inflammation of variety of conditions and diseases |
| 02/10/2005 | US20050032820 Novel spiro compounds |
| 02/10/2005 | US20050032817 Kinesin spindle protein (KSP) inhibitors, e.g., 3-benzyl-2-(1-{(4-bromobenzyl)[2-(dimethylamino)ethyl]amino}propyl)furo[2,3-d]pyrimidin-4(3H)-one; antiproliferative and -carcinogenic agents; side effects reduction; cancers of the brain, genitourinary tract, lymphatic system, stomach, larynx and lung |
| 02/10/2005 | US20050032816 N-oxide anthranylamide derivatives and their use as medicaments |
| 02/10/2005 | US20050032815 Preventing dermatitis in a human by administering a composition consisting of therapeutically effective amounts of optically pure (-) cetirizine or salt thereof, and a leukotriene inhibitor or salt thereof; synergistic mixture; also useful as asthma treatment |
| 02/10/2005 | US20050032813 Methods of use of fluoroquinolone compounds against maxillary sinus pathogenic bacteria |
| 02/10/2005 | US20050032812 Administering a dopamine D1, D2, D3, and D4 receptor agonist such as pramipexole or talipexol; for treating overweight or obesity or type 2 diabetes |
| 02/10/2005 | US20050032811 Composition comprising aripiprazole and a carrier such as carboxymethyl cellulose administered in a bolus injection resulted in an extended release profile similar to that obtained by the injection of a poly lactide-co-glycolide microsphere formulation containing the active agent; efficiency |
| 02/10/2005 | US20050032809 5-HT receptor ligands and uses thereof |
| 02/10/2005 | US20050032808 Pyrazine carboxamide compounds for use in treatment of obesity, psychiatric and neurological disorders; for example, N-(1-piperidinyl)-5,6-diphenyl-2-pyrazinecarboxamide |
| 02/10/2005 | US20050032807 Treatment of cellular tumor growth, tumor proliferation or metastasis using ammonium salts of N delta -acyl derivatives of N alpha (4-amino-4-deoxypteroyl)-L-ornithine compounds |
| 02/10/2005 | US20050032806 Method for treating anhedonia using dopamine agonists |
| 02/10/2005 | US20050032805 Antimicrobial biaryl compounds |
| 02/10/2005 | US20050032804 Dihydrogenphosphate salt of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine; inhibitor of dipeptidyl peptidase-IV, useful for the prevention and/or treatment of non-insulin dependent diabetes mellitus |
| 02/10/2005 | US20050032803 as modulators of receptor tyrosine kinases and cytoplasmic tyrosine and serine/threonine kinases; can bind both to active and also to non-active kinases and therefore influence the signal transduction |
| 02/10/2005 | US20050032802 Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents |
| 02/10/2005 | US20050032801 Compositions containing a ruthenium(III) complex and a heterocycle |
| 02/10/2005 | US20050032799 Treating a CNS disorder by orally administering to a patient a therapeutically effective amount of lamotrigine or a pharmaceutically acceptable derivative; for treatment of epilepsy, pain, edema, multiple sclerosis, psychological disorders, schizophrenia, bipolar disorders; side effect reduction |
| 02/10/2005 | US20050032798 Diaryl ureas, which release urea compound when administered to patient, for example, 1-(4-chloro-3(trifluoromethyl)phenyl)-3-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)-2-oxo-(1,3,5-perhydrotriazapine); treatment of cancer, inflammation |
| 02/10/2005 | US20050032794 For example, 2-Dimethylamino-N-(3-dimethylamino-1,4-dioxo-1,4-dihydro-naphthalen-2-yl)-N-methyl-acetamide; ability to function as gene expression modulators for genes found in cancer cells, especially genes involved in misregulated signal transduction pathways typical of cancers of colon and breast |
| 02/10/2005 | US20050032793 For example, 1,1-dimethylethyl [2-[[2-(diethylamino)-2-oxo-1S-(phenylmethyl)ethyl]amino]-5-methyl-4-oxo-4H-3,1-benzoxazin-6-yl]carbamate; for treating herpes-related disorders |
| 02/10/2005 | US20050032792 Peptidyl spiroheterocyclic, amidino and guanidino compounds; reversible inhibitors of the cysteine protease cathepsin S, K, F, L and B; useful in the treatment of autoimmune and other related diseases |
| 02/10/2005 | US20050032791 Derivatives of sulphonamides, their preparation and use as medicaments |
| 02/10/2005 | US20050032788 treating fibrotic lung diseases and fibrotic hypertrophy or fibrosis of prostate, liver, the pleura, pancreas or bowel wall with saturated and unsaturated azoles and salts, e.g., 3-[2-phenyl-2-oxoethyl]-4,5-dimethyl-thiazolium salt |
| 02/10/2005 | US20050032787 Pheny (alkyl)carboxylic acid derivatives and dionic phenylalkylheterocyclic derivatives and their use as medicines with serum glucose and/or serum lipid lowering activity |
| 02/10/2005 | US20050032786 1, 3-benzothiazinone derivatives and use thereof |
| 02/10/2005 | US20050032785 LIVER CANCER; ADMINISTERING TAUROLIDINE, direct contact a liver tissue by perfusion in situ, to increase caspase activity in a cell; monitoring the treatment |
| 02/10/2005 | US20050032784 administering mixtures of carriers or excipients and angiotensin-converting-enzyme inhibitors, calcium channel blockers anddiuretic, as hypotensive agents |
| 02/10/2005 | US20050032783 Use of CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients |
| 02/10/2005 | US20050032782 Treatment of chronic pain associated with drug or radiation therapy |
| 02/10/2005 | US20050032781 Methods for administering active agents to CYP 2D6 sensitive patients |
| 02/10/2005 | US20050032780 Method of treating functional bowel disorders |
| 02/10/2005 | US20050032779 enzyme inhibitors such as 2-[4-(4-Dimethylaminophenyl)piperazin-1-yl]4,5-dihydroimidazo[4,5,1-ij]quinolin-6-one, used for treating or preventing disorders in which poly/ADP-ribose/ polymerase is involved |
| 02/10/2005 | US20050032778 Therapeutically active thiophenepyrimidinone compounds and their use |
| 02/10/2005 | US20050032777 benzyl carbamates and ureas such as 5-(4-(4-cyclopropylmethylpiperazine-1-carbonylaminomethyl)-3-methylbenzoyl)-1-methyl-4,10-dihydropyrazolo[5,4-b][1,5]benzodiazepine, used for treatment of sexual disorders |
| 02/10/2005 | US20050032776 Benzothiazepine derivatives for the treatment of hyperlipidemia |
| 02/10/2005 | US20050032774 Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity |
| 02/10/2005 | US20050032773 Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositons comprising them and their use in the treatment of obesity |
| 02/10/2005 | US20050032772 Compounds useful as reversible inhibitors of cysteine proteases |
| 02/10/2005 | US20050032771 Process for the preparation of cefixime via alkyl-or aryl-sulfonates |
| 02/10/2005 | US20050032770 Methods of treatment of chronic immune disease |
| 02/10/2005 | US20050032768 pentsaaacycle manganese complexes used as mimetics for oxidoreductase enzymes, for the treatment of age-related macular degeneration, diabetic retinopathy and edema; vision defects |
| 02/10/2005 | US20050032767 Method for obtaining a natural mixture of conjugated equine estrogens |
| 02/10/2005 | US20050032766 Use of estrogenic compounds as anti-fungal agents |
| 02/10/2005 | US20050032765 Steroid derived antibiotics |